1. [1] Abozguia K, Chudley S., Gammage M. Dose-dependent venlafaxine-induced sinus tachycardia. Int J Cardiol. 2006;113:E9-E10
2. [2] Hanash JA, Hansen BH, Hansen JF, Nielsen OW, Rasmussen A, Birket-Smith M. Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the Depression in patients with Coronary Artery Disease (DECARD) trial. J Cardiovasc Pharmacol. 2012;60(4): 397-405.
3. [3] Leonard C.E., Bilker W.B., Newcomb C., Kimmel S.E., Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol. Drug Saf. 2011;20: 903-913.
4. [4] Ma-Li, Wong D.CH., Esporito K., Thakur S., Liu W., Elashoff R.M., Licinio J. Elevated Stress-Hemoconcentration in Major Depression is Normalized by Antidepressant Treatment: Secondary Analysis for a Randomized, Double-Blind Clinical Trial and Relevance to Cardiovascular Disease Risk. PLOS ONE. 2008;7: 1-6.
5. [5] Nezafati M, Vojdanparast M, Nezafati P. Antidepressants and cardiovascular adverse events: A narrative review. ARYA Atherosclerosis. 2015;11(5):295-304.